Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rosenquist

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Leukemia|February 23, 2018
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretationJ Malcikova, E Tausch, D Rossi, et al.
Acta Oncologica (Stockholm, Sweden)|July 7, 2023
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first resultsK E Smedby, T Wästerlid, E Tham, et al.
Leukemia|November 5, 2011
Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activityE Kostareli, M Gounari, A Janus, et al.
Leukemia|April 6, 2013
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2J C Strefford, L-A Sutton, P Baliakas, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
Journal of Internal Medicine|July 2, 2021
Technological readiness and implementation of genomic-driven precision medicine for complex diseasesP W Franks, E Melén, M Friedman, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Leukemia|June 11, 2016
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaH Parker, M J J Rose-Zerilli, M Larrayoz, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Leukemia|February 23, 2018
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretationJ Malcikova, E Tausch, D Rossi, et al.
Acta Oncologica (Stockholm, Sweden)|July 7, 2023
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first resultsK E Smedby, T Wästerlid, E Tham, et al.
Leukemia|November 5, 2011
Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activityE Kostareli, M Gounari, A Janus, et al.
Leukemia|April 6, 2013
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2J C Strefford, L-A Sutton, P Baliakas, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
Journal of Internal Medicine|July 2, 2021
Technological readiness and implementation of genomic-driven precision medicine for complex diseasesP W Franks, E Melén, M Friedman, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Leukemia|June 11, 2016
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaH Parker, M J J Rose-Zerilli, M Larrayoz, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
Pageof 6